Aerovate Therapeutics AVTE

$

9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
.
9
8
7
6
5
4
3
2
1
0
0
+$0.03 (+1.20%)Past DayToday's Volume:
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
,
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0

Relative Strength Index (RSI)

- The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.

- The RSI is calculated using the following formula:

RSI = 100 - (100 / (1 + RS))

Where RS is the ratio of the average gains to the average losses over a specified period.

- The default time period used is 14 days.

- RSI values range between 0 and 100.

RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)

RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)

RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.

About

Business overview of Aerovate Therapeutics (AVTE)
Aerovate Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing drugs that improve the lives of patients with rare cardiopulmonary disease. The initial focus of the company is on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension.

Key Insights

Critical company metrics and information

  • Latest Closing Price

    $2.53

  • Market Cap

    $73.33 Million

  • Price-Earnings Ratio

    -0.85

  • Total Outstanding Shares

    28.88 Million Shares

  • Total Employees

    51

  • Dividend

    No dividend

  • IPO Date

    June 30, 2021

  • SIC Description

    Pharmaceutical Preparations

  • Primary Exchange

    NASDAQ

  • Type

    Common Stock

  • Headquarters

    930 winter street, Waltham, MA, 02451

  • Homepage

    https://www.aerovatetx.com

Historical Stock Splits

Execution DateSplit Amount
No Historical Stock Splits

Cash Flow Statement

October 1, 2023 to September 30, 2024
MetricValue
Net Cash Flow From Operating Activities$-74.95 Million
Net Cash Flow From Financing Activities$25.34 Million
Net Cash Flow From Financing Activities, Continuing$25.34 Million
Net Cash Flow$-1.06 Million
Net Cash Flow From Investing Activities, Continuing$48.55 Million
Net Cash Flow, Continuing$-1.06 Million

Income Statement

October 1, 2023 to September 30, 2024
MetricValue
Other Operating Expenses$20.79 Million
Income/Loss From Continuing Operations After Tax$-84.61 Million
Operating Expenses$90.26 Million
Operating Income/Loss$-90.26 Million
Revenues$0
Net Income/Loss Attributable To Parent$-84.61 Million

Comprehensive Income

October 1, 2023 to September 30, 2024
MetricValue
Other Comprehensive Income/Loss$447,000
Comprehensive Income/Loss Attributable To Noncontrolling Interest$0
Comprehensive Income/Loss Attributable To Parent$-84.16 Million
Comprehensive Income/Loss$-84.16 Million

Balance Sheet

October 1, 2023 to September 30, 2024
MetricValue
Equity Attributable To Noncontrolling Interest$0
Equity Attributable To Parent$80.49 Million
Prepaid Expenses$993,000
Other Current Assets$912,000
Noncurrent Assets$354,000
Cash$88.70 Million

Historical Dividends

Announcement DatePayment DateRecord DateAmountFrequency
No historical dividends

Recent Headlines From The Web

Latest news, press releases, and media coverage about AVTE from trusted financial sources
    All TickersEarnings CalendarNews ArticlesAbout UsPrivacy & Cookies Info

    â“’ 2025 Financhle. All Rights Reserved.